MHRA, GMP & Regulatory Compliance Insurance Guide

CALL FOR EXPERT ADVICE
GET A QUOTE

A practical guide for UK pharmaceutical manufacturers and CDMOs: how MHRA/GMP compliance connects to insurance, what insurers ask, and how to reduce coverage gaps after audits, deviations or enforcement activity.

CALL FOR EXPERT ADVICE
GET A QUOTE

We compare quotes from leading insurers

  • Allianz
  • Aviva
  • QBE
  • RSA
  • Zurich
  • NIG

COMPLIANCE INSIGHT THAT HELPS YOU TAKE OFF

Compliance and Insurance Are Linked — Whether You Like It or Not

In pharmaceutical manufacturing, regulatory compliance isn’t just a quality issue; it’s a business continuity issue. MHRA inspections, GMP deviations and quality system failures can trigger product quarantines, shipment stops, customer audits, and in severe cases forced shutdowns. Even when no patient harm occurs, the financial impact can be substantial: additional testing, remediation, revalidation, lost production, contractual penalties and reputational damage.

Insurance is not a substitute for compliance, and it doesn’t “cover fines for being non-compliant”. But insurance programmes can be structured to respond to the kinds of losses that often arise alongside compliance events — for example product withdrawal costs, liability claims, business interruption following damage or breakdown, and (in some cases) crisis costs.

This guide explains how MHRA/GMP reality intersects with insurance in the UK, what insurers typically ask for during underwriting, and how to avoid common coverage gaps that appear after audits, deviations, contamination investigations or enforcement action.

How MHRA & GMP Compliance Shows Up in Insurance

Insurers don’t underwrite “GMP” in the abstract. They underwrite the consequences of GMP success or failure: the likelihood of batch defects, contamination, mislabelling, stability failures, and the ability of the business to detect issues quickly and limit their scope. Put simply, strong compliance tends to reduce both frequency (fewer incidents) and severity (shorter incidents).

MHRA inspections and GMP audits are relevant because they can reveal systemic issues that increase loss probability: data integrity weaknesses, inadequate validation, poor change control, weak supplier management, or recurring environmental excursions. Underwriters may ask about inspection outcomes and major observations because these indicate how robust your control environment is.

Your insurance programme can’t “erase” a compliance problem, but it can be structured so that when an incident triggers operational costs — quarantine, withdrawal, replacement, extra expense and downtime — you have a clearer route to financial support (subject to policy triggers and wording).

Where Compliance Creates Loss Exposure

  • Batch rejection and disposal following investigation outcomes
  • Product quarantine and delayed release (testing backlog, QA decisions)
  • Production shutdowns during remediation and revalidation
  • Withdrawal/recall logistics and customer communications
  • Customer audits and contractual non-conformance claims

The biggest cost driver is often time: how long it takes to restore a compliant, auditable state. That directly affects business interruption exposure.

Where Insurance Typically Can (and Can’t) Help

  • Can help: liability claims, recall/withdrawal costs (if purchased), BI after insured events, stock loss due to insured perils
  • Usually can’t: regulatory fines and penalties, the cost of “becoming compliant” as a routine operational expense
  • Depends on wording: non-damage shutdown triggers, contamination exclusions, definitions of defect/withdrawal

The key is alignment: policy wording must match your operational and regulatory realities, otherwise you may discover the gap only during a claim.

CALL FOR EXPERT ADVICE
GET A QUOTE

What Insurers Typically Ask About MHRA/GMP

Insurers need to understand your risk profile, your control environment, and how quickly you can detect and contain quality issues. This doesn’t mean you need to share every SOP — but you should be prepared to explain your quality system maturity, inspection history at a high level, and key controls that reduce the chance of high-severity events.

The information below is commonly requested for product liability, recall/withdrawal and property/BI underwriting in pharmaceutical manufacturing.

Quality System & Oversight

  • MHRA inspection outcomes (high-level) and timing of last inspection
  • QMS structure, QA independence and management review cadence
  • Deviation/CAPA process and trending approach
  • Change control discipline and validation governance
  • Data integrity controls (access, audit trails, backup and review)

Insurers are looking for “signal”: do you have a system that detects issues early and prevents repeated high-impact deviations?

Manufacturing & Facility Controls

  • Cleanroom classifications and environmental monitoring programme
  • Segregation strategy (product families, potency, allergens)
  • Cleaning validation/verification strategy and line clearance controls
  • Supplier qualification and incoming testing approach
  • Utilities resilience (HVAC, PW/WFI, compressed air, power backup)

Underwriters also care about single points of failure and recovery capability. Redundancy and documented response plans reduce downtime severity.

CALL FOR EXPERT ADVICE
GET A QUOTE NOW

Common Coverage Gaps After Compliance Events (and How to Avoid Them)

Compliance-driven incidents often create costs before any third-party claim exists. That’s where gaps appear. If your programme is built only around “injury claims” or “fire/flood damage”, it may not respond to the costs you actually face during an MHRA-driven shutdown or major deviation investigation.

The good news is that gaps are usually avoidable at placement stage — by choosing the right mix of covers, setting realistic indemnity periods, and ensuring your business description and processes are accurately disclosed.

Gap 1: Recall Assumed to Be Included

A common mistake is assuming product liability will pay for recall/withdrawal logistics. Often it won’t. Product liability is built for third-party claims; recall is a first-party cost cover.

  • Solution: include a dedicated recall/withdrawal section if your exposure is material
  • Ensure triggers suit your reality (voluntary vs regulatory ordered withdrawals)
  • Align cover to territories and distribution model

Gap 2: BI Indemnity Period Too Short for GMP Recovery

GMP downtime can be driven by investigation, cleaning and revalidation — not just repair. A 12-month indemnity period can be inadequate for complex facilities or single-line bottlenecks.

  • Solution: choose an indemnity period aligned to “compliant production restored”
  • Consider equipment lead times, requalification and customer re-approval
  • Review sums insured against realistic gross profit exposure

Gap 3: Contamination/Defect Definitions Are Too Narrow

Some policies contain broad contamination exclusions or tight definitions of “defect”. If the wording doesn’t match your risk pathways, you can be left with uninsured investigation and withdrawal costs.

  • Solution: review contamination, pollution and defect definitions carefully
  • Disclose sterile operations, potent compounds and shared facilities correctly
  • Structure recall/withdrawal and BI with realistic triggers

Gap 4: Contract Terms Not Reflected in Insurance

Quality agreements can allocate recall costs, impose notification obligations and include indemnities. If your insurance programme doesn’t reflect these, you can have a contractual liability that the policy excludes.

  • Solution: map key contracts, indemnities and required limits
  • Clarify responsibility for client-owned materials and stock
  • Ensure insured parties and “contractual liability” wording are aligned
CALL FOR EXPERT ADVICE
GET A QUOTE NOW
Quote icon

“After an inspection-driven remediation, we realised our biggest cost was downtime and extra testing — not just physical damage. Aligning recall and BI cover made our programme far more resilient.”

QA Lead, UK Pharmaceutical Manufacturer

UNIQUE INSURANCE
TAILORED FOR YOU 

PROTECT YOURSELF

  • Better alignment between compliance reality and insurance triggers
  • Recall/withdrawal cover for first-party logistics costs (where needed)
  • BI structured around GMP recovery timelines
  • Clarity on contamination wording and exclusions
  • Support in presenting controls and inspection history to insurers

Insure24 helps pharmaceutical manufacturers and CDMOs arrange insurance programmes that fit regulated manufacturing. We’ll help you present your quality controls and operational resilience clearly, then structure cover to reduce gaps that often appear after audits, deviations and remediation events.

If you’re unsure whether your current programme truly matches your MHRA/GMP exposure, call 0330 127 2333 for a quick, practical conversation.

CALL FOR EXPERT ADVICE
GET A QUOTE

FREQUENTLY ASKED QUESTIONS

+-

Does insurance cover MHRA fines or penalties?

Typically no. Insurance generally does not cover regulatory fines and penalties for non-compliance. However, an insurance programme can be structured to respond to certain losses that may arise alongside compliance events, such as recall/withdrawal costs (if purchased), liability claims, and business interruption triggered by insured events.

+-

Will product liability cover costs from a GMP deviation?

Product liability mainly covers third-party injury/illness or third-party property damage claims and associated legal defence. Many GMP deviations create first-party operational costs (quarantine, additional testing, remediation, withdrawal logistics) before any third-party claim exists, so product liability alone may not address the main costs you face.

+-

Why do insurers ask about inspection findings and CAPAs?

Inspection outcomes and CAPA effectiveness are indicators of how well a business detects, corrects and prevents quality issues. Strong controls reduce incident frequency and severity, which improves insurability. Insurers usually want a high-level overview rather than exhaustive detail.

+-

Does business interruption cover downtime from an inspection-driven shutdown?

It depends on policy triggers. Many BI policies are linked to physical damage, while inspection-driven shutdowns may be non-damage events. Some programmes can include extensions or specialist structures for certain non-damage triggers, but cover is highly wording-dependent and insurer appetite varies.

+-

What are the most common insurance gaps linked to compliance events?

Common gaps include assuming recall is covered under product liability, inadequate BI indemnity periods for GMP recovery, restrictive contamination/defect definitions, and insurance programmes that don’t align with contractual responsibility for recall and client-owned stock.

+-

How do I get a quote that reflects our compliance profile properly?

Call 0330 127 2333 or request a quote online. We’ll discuss your activities, territories, quality controls, inspection history at a high level, and key operational dependencies, then structure a submission that helps insurers understand your compliance environment and provide accurate terms.
CALL FOR EXPERT ADVICE
GET A QUOTE

Related Blogs